Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06069622 · ClinicalTrials.gov registry record
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
A clinical trial of Overweight and Obesity, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06069622: Recruiting study of Overweight and Obesity, sponsored by Brigham and Women's Hospital.
NCT06069622 is a study of Overweight and Obesity that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants, below the 228-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06069622, a study of Overweight and Obesity, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Obesity has become an important public health issue that leads to insulin resistance, diabetes, hypertension, dyslipidemia, and cardiovascular diseases. Although weight loss with calorie restriction and increased physical activity improve these complications, many people fail these lifestyle interventions. Therefore, pharmacologic agents have been used for weight management in addition to lifestyle interventions. In the past few years, one of the widely used pharmacologic agents for weight management is Glucagon-like peptide 1 receptor agonists (GLP1 RAs). Overall, this class of medications improves both metabolic and cardiovascular profiles while causing weight loss, but their effects can vary between individuals. Therefore, it is essential to understand who will respond best to this therapy. Based on previous research on the interaction between a cell membrane molecule, caveolin-1, and glucagon-like peptide 1 receptor, we hypothesize that genetic variations in the caveolin-1 gene explain the variable cardiometabolic responses.
Primary Outcome
The primary outcome will be the change (pre- treatment minus post-treatment) in mean 24-hour ambulatory systolic BP on a controlled dietary sodium intake in both CAV1 non-risk and risk genotypes.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 24-hour ambulatory blood pressure
- DIETARY_SUPPLEMENT Liberal salt diet
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2026-11-30 |
What NCT06069622 shows while recruiting
NCT06069622 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 228-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Overweight and Obesity appearing as the primary indexed condition, and to 2 interventions - of which 24-hour ambulatory blood pressure is the first listed.
NCT06069622 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06069622 about?
NCT06069622 is a clinical study titled "Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment". Obesity has become an important public health issue that leads to insulin resistance, diabetes, hypertension, dyslipidemia, and cardiovascular diseases. Although weight loss with calorie restriction and increased physical activity improve these complications, many people fail these lifestyle interve...
What is the current status of trial NCT06069622?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-11-01. Estimated completion is 2026-11-30.
What conditions does trial NCT06069622 study?
This clinical trial studies the following conditions: Overweight and Obesity.
What interventions are being tested in trial NCT06069622?
The interventions under investigation include: 24-hour ambulatory blood pressure (DIAGNOSTIC_TEST), Liberal salt diet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06069622?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06069622 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight and Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06069622's enrollment target sits among peer trials
30 99th of 115 higher than 16 of 115 other Overweight and Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overweight and Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Breathing & Blood Pressure
RECRUITING
-
A Pilot Factorial Trial of an Integrated Lifestyle Intervention
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
Cooking Skills to Improve Long-Term Weight Loss in Young Adults With Intellectual Disabilities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI